Bio-S: Subsidiary Saimo Pharmaceutical plans to win bids for 12 varieties in the 11th national drug procurementZhitong·Nov 3, 2025 at 06:59 PM301096+5.17%
The three major A-share indices opened lower collectively, with new stock N Danna soaring 447.95% on its first day of listing36Kr·Nov 2, 2025 at 07:31 PM000892+10.15%301096+5.17%
Bio-S released its performance for the first three quarters, with a net profit attributable to the parent company of 6.1242 million yuan, a decrease of 95.68%Zhitong·Oct 24, 2025 at 08:01 AM301096+5.17%
Bio-S: Innovative drug BIOS-0623-Z4 tablets have received clinical trial approvalZhitong·Sep 29, 2025 at 04:08 AM301096+5.17%
Innovative drug concept stocks surged and then fell back, with Mengke Pharmaceutical dropping over 10%, BrightGene, Bio-S falling over 7%, and YKYY, Konruns, EASTON BIOPHARMACEUTICALS, Fushine among those with the largest declinesZhitong·Sep 25, 2025 at 12:43 AM688166+3.49%301096+5.17%
Understanding the Market | XTALPI rose nearly 7% in the morning session as the company signed a letter of intent for cooperation with Bio-S to jointly promote AI new drug research and development cooperationZhitong·Sep 24, 2025 at 08:45 PM02228+6.21%301096+5.17%
Bio-S and others establish a new venture capital partnership for the transformation of scientific and technological achievementsZhitong·Sep 23, 2025 at 10:02 PM301096+5.17%
Bio-S's subsidiary Hangzhou Mipeng plans to invest 15 million yuan in a partnership enterprise to layout strategic emerging industries such as biomedicine and hard technologyZhitong·Sep 22, 2025 at 05:47 AM301096+5.17%
Bio-S: Jia Fei plans to reduce his holdings by 0.0112% within three monthsZhitong·Sep 22, 2025 at 05:40 AM301096+5.17%
Bio-S: The upper limit for the increase in holdings is adjusted to 80 yuanZhitong·Sep 11, 2025 at 03:33 AM301096+5.17%
Ophthalmology medical concept stocks surged, SPAS hit the daily limit in the afternoonZhitong·Sep 1, 2025 at 12:54 AM003020+4.39%301096+5.17%
Bio-S released its performance for the first half of the year, with a net profit attributable to the parent company of 3.0982 million yuan, a decrease of 97.69%Zhitong·Aug 26, 2025 at 09:47 AM301096+5.17%
Bio-S and others establish a new life and health venture capital partnership with an investment amount of 500 million yuanZhitong·Aug 14, 2025 at 01:38 AM301096+5.17%
Bio-S expects a net profit attributable to the parent company of RMB 0 to 6 million in the first half of the year, a year-on-year decrease of 95.53% to 100%Zhitong·Jul 15, 2025 at 06:43 AM301096+5.17%
CRO concept stocks partially rose, Lionco surged to the daily limitZhitong·Jun 29, 2025 at 08:50 PM301096+5.17%688602+0.95%
